Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Bascom Palmer Eye Institute, Miami, Florida

West Virginia University Eye Institute, Morgantown, West Virginia